Detalles de la búsqueda
1.
3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial.
Lancet
; 403(10437): 1649-1659, 2024 Apr 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-38582092
2.
Clinicopathological and molecular predictors of [18F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial.
Eur J Nucl Med Mol Imaging
; 2024 Apr 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-38587643
3.
Trastuzumab and pertuzumab without chemotherapy in early-stage HER2+ breast cancer: a plain language summary of the PHERGain study.
Future Oncol
; 18(33): 3677-3688, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-36300423
4.
Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial.
Lancet Oncol
; 22(6): 858-871, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-34019819
5.
Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer.
Br J Cancer
; 122(5): 603-612, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31839676
6.
How COVID-19 pandemic affected cancer progression: Three different scenarios evidenced by PET imaging.
Hell J Nucl Med
; 23(3): 349-353, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-33306764
7.
Optimal [18F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial.
J Nucl Med
; 65(5): 708-713, 2024 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38575192
8.
Molecular imaging predicts lack of T-DM1 response in advanced HER2-positive breast cancer (final results of ZEPHIR trial).
NPJ Breast Cancer
; 10(1): 4, 2024 Jan 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-38184611
9.
PIK3CA copy-number gain and inhibitors of the PI3K/AKT/mTOR pathway in triple-negative breast cancer.
Cold Spring Harb Mol Case Stud
; 9(2)2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36863843
10.
[18F]FDG and [18F]FES PET/CT Imaging as a Biomarker for Therapy Effect in Patients with Metastatic ER+ Breast Cancer Undergoing Treatment with Rintodestrant.
Clin Cancer Res
; 29(11): 2075-2084, 2023 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36735488
11.
New PET imaging agents in the management of solid cancers.
Curr Opin Oncol
; 24(6): 748-55, 2012 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-22913970
12.
WITHDRAWN:New PET imaging agents in the management of solid cancers.
Curr Opin Oncol
; 2012 Mar 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-22410459
13.
Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant.
Eur J Cancer
; 164: 39-51, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35172272
14.
FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer.
NPJ Breast Cancer
; 7(1): 125, 2021 Sep 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-34548493
15.
Added value of para-aortic surgical staging compared to 18F-FDG PET/CT on the external beam radiation field for patients with locally advanced cervical cancer: An ONCO-GF study.
Eur J Surg Oncol
; 46(5): 883-887, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31784203
16.
Molecular Imaging in Breast Cancer: Martine Piccart and Géraldine Gebhart Talk with David Mankoff About 2 Generations of Research.
J Nucl Med
; 2024 Feb 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-38331455
17.
Tumor Drug Penetration Measurements Could Be the Neglected Piece of the Personalized Cancer Treatment Puzzle.
Clin Pharmacol Ther
; 106(1): 148-163, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30107040
18.
18F-FDG PET "Metabolic Response" to Neoadjuvant Systemic Therapy for Breast Cancer: Quo Vadis?
J Nucl Med
; 64(11): 1697-1698, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37918851
19.
Strategies and technical challenges for imaging oligometastatic disease: Recommendations from the European Organisation for Research and Treatment of Cancer imaging group.
Eur J Cancer
; 91: 153-163, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29331524
20.
HER2-positive breast cancer is lost in translation: time for patient-centered research.
Nat Rev Clin Oncol
; 14(11): 669-681, 2017 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-28762384